Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
América Móvil, S.A.B. de C.V. stock logo
AMOV
América Móvil
$20.75
-1.1%
$20.58
$15.86
$22.57
N/AN/A3,310 shs1,000 shs
COMSovereign Holding Corp. stock logo
COMSP
COMSovereign
$0.40
$0.44
$0.30
$4.60
N/AN/A889 shs1 shs
CYTHW
Cyclo Therapeutics
$0.22
-18.5%
$0.28
$0.13
$0.50
N/AN/A2,392 shs11,507 shs
GeoVax Labs, Inc. stock logo
GOVXW
GeoVax Labs
$0.03
$0.03
$0.02
$0.28
N/AN/A4,011 shs95 shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
América Móvil, S.A.B. de C.V. stock logo
AMOV
América Móvil
0.00%0.00%0.00%0.00%0.00%
COMSovereign Holding Corp. stock logo
COMSP
COMSovereign
0.00%0.00%0.00%-42.86%-84.00%
CYTHW
Cyclo Therapeutics
-18.52%-24.14%-24.14%-26.42%-12.00%
GeoVax Labs, Inc. stock logo
GOVXW
GeoVax Labs
0.00%-30.86%-13.97%+13.86%-75.37%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
América Móvil, S.A.B. de C.V. stock logo
AMOV
América Móvil
N/AN/AN/AN/AN/AN/AN/AN/A
COMSovereign Holding Corp. stock logo
COMSP
COMSovereign
N/AN/AN/AN/AN/AN/AN/AN/A
CYTHW
Cyclo Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
GeoVax Labs, Inc. stock logo
GOVXW
GeoVax Labs
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
América Móvil, S.A.B. de C.V. stock logo
AMOV
América Móvil
N/AN/AN/AN/A
COMSovereign Holding Corp. stock logo
COMSP
COMSovereign
N/AN/AN/AN/A
CYTHW
Cyclo Therapeutics
N/AN/AN/AN/A
GeoVax Labs, Inc. stock logo
GOVXW
GeoVax Labs
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
América Móvil, S.A.B. de C.V. stock logo
AMOV
América Móvil
$844.50KN/AN/AN/AN/AN/A
COMSovereign Holding Corp. stock logo
COMSP
COMSovereign
$6.17MN/AN/AN/AN/AN/A
CYTHW
Cyclo Therapeutics
$1.08MN/AN/AN/AN/AN/A
GeoVax Labs, Inc. stock logo
GOVXW
GeoVax Labs
$81.53KN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
América Móvil, S.A.B. de C.V. stock logo
AMOV
América Móvil
N/A$21.760.95N/AN/AN/AN/AN/A
COMSovereign Holding Corp. stock logo
COMSP
COMSovereign
N/AN/A0.00N/AN/AN/AN/AN/A
CYTHW
Cyclo Therapeutics
N/AN/A0.00N/AN/AN/AN/AN/A
GeoVax Labs, Inc. stock logo
GOVXW
GeoVax Labs
N/AN/A0.00N/AN/AN/AN/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
América Móvil, S.A.B. de C.V. stock logo
AMOV
América Móvil
$3.8118.35%N/A17.50%1 Years
COMSovereign Holding Corp. stock logo
COMSP
COMSovereign
N/AN/AN/AN/AN/A
CYTHW
Cyclo Therapeutics
N/AN/AN/AN/AN/A
GeoVax Labs, Inc. stock logo
GOVXW
GeoVax Labs
N/AN/AN/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
América Móvil, S.A.B. de C.V. stock logo
AMOV
América Móvil
0.05%
COMSovereign Holding Corp. stock logo
COMSP
COMSovereign
N/A
CYTHW
Cyclo Therapeutics
N/A
GeoVax Labs, Inc. stock logo
GOVXW
GeoVax Labs
N/A

Insider Ownership

CompanyInsider Ownership
América Móvil, S.A.B. de C.V. stock logo
AMOV
América Móvil
N/A
COMSovereign Holding Corp. stock logo
COMSP
COMSovereign
N/A
CYTHW
Cyclo Therapeutics
N/A
GeoVax Labs, Inc. stock logo
GOVXW
GeoVax Labs
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
América Móvil, S.A.B. de C.V. stock logo
AMOV
América Móvil
181,205N/AN/ANot Optionable
COMSovereign Holding Corp. stock logo
COMSP
COMSovereign
25N/AN/ANot Optionable
CYTHW
Cyclo Therapeutics
8N/AN/ANot Optionable
GeoVax Labs, Inc. stock logo
GOVXW
GeoVax Labs
17N/AN/ANot Optionable

GOVXW, CYTHW, AMOV, and COMSP Headlines

SourceHeadline
GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 VaccineGeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine
finance.yahoo.com - April 4 at 1:25 PM
GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine CongressGeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress
finance.yahoo.com - March 28 at 9:06 AM
GeoVax Announces Multiple Patent Issuances and AllowancesGeoVax Announces Multiple Patent Issuances and Allowances
finance.yahoo.com - February 13 at 10:08 AM
GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine BoosterGeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster
finance.yahoo.com - February 6 at 9:55 AM
GeoVax, Inc.: GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid RequirementGeoVax, Inc.: GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement
finanznachrichten.de - January 29 at 12:22 PM
EQS-News: GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid RequirementEQS-News: GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement
markets.businessinsider.com - January 29 at 12:22 PM
GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid RequirementGeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement
finance.yahoo.com - January 29 at 12:22 PM
GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer PatientsGeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients
finance.yahoo.com - January 4 at 9:38 AM
GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024
finance.yahoo.com - December 27 at 10:06 AM
GeoVax, Inc.: GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and SmallpoxGeoVax, Inc.: GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox
finanznachrichten.de - December 19 at 12:24 PM
GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and SmallpoxGeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox
finance.yahoo.com - December 19 at 12:24 PM
Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023
finance.yahoo.com - November 14 at 9:23 AM
GeoVax Reports Third Quarter 2023 Financial Results and Provides Business UpdateGeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update
finance.yahoo.com - November 8 at 6:49 PM
GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 VaccineGeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine
finance.yahoo.com - October 30 at 11:43 AM
GeoVax to Participate in Upcoming November Investor and Industry EventsGeoVax to Participate in Upcoming November Investor and Industry Events
finance.yahoo.com - October 25 at 10:07 AM
GeoVax Receives Notice of Allowance for Marburg Vaccine PatentGeoVax Receives Notice of Allowance for Marburg Vaccine Patent
finance.yahoo.com - October 9 at 10:35 AM
GeoVax Receives Notice of Allowance for HIV Vaccine PatentGeoVax Receives Notice of Allowance for HIV Vaccine Patent
finance.yahoo.com - October 5 at 9:54 AM
GeoVax licenses suspension cell line tech for vax portfolioGeoVax licenses suspension cell line tech for vax portfolio
bioprocessintl.com - October 2 at 8:26 AM
GeoVax Secures Multi-Product License for ProBioGens AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine DevelopmentGeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development
finance.yahoo.com - September 26 at 10:29 AM
GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia ConferenceGeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference
finance.yahoo.com - September 20 at 10:01 AM
GeoVax to Present at the Emerging Growth Conference on September 6, 2023GeoVax to Present at the Emerging Growth Conference on September 6, 2023
finance.yahoo.com - August 29 at 2:58 PM
GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic LeukemiaGeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia
finance.yahoo.com - August 10 at 9:02 AM
GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate UpdateGeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update
finance.yahoo.com - August 9 at 7:43 PM
GeoVax Labs Shares Rise 8% After Patent for Ebola VaccineGeoVax Labs Shares Rise 8% After Patent for Ebola Vaccine
marketwatch.com - July 24 at 12:21 PM

Media Sentiment Over Time

Company Descriptions

América Móvil logo

América Móvil

NYSE:AMOV
America Movil SAB de CV engages in the provision of telecommunications services. The firm operates through the following segments: Mexico Wireless, Mexico Fixed, Brazil, Colombia, Southern Cone (Argentina, Chile, Paraguay and Uruguay), Andean Region (Ecuador and Peru), Central America (Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua and Panama), the Caribbean (the Dominican Republic and Puerto Rico) and Europe (Austria, Belarus, Bulgaria, Croatia, Macedonia, Serbia and Slovenia). Its products and services include wireless voice, wireless data and value-added services, fixed voice, fixed data, broadband and IT services, Pay TV and over-the-top (OTT) services. The company was founded on September 25, 2000 and is headquartered in Mexico City, Mexico.
COMSovereign logo

COMSovereign

NASDAQ:COMSP
COMSovereign Holding Corp. provides various solutions for network operators, mobile device carriers, governmental units, and other enterprises worldwide. The company offers packet microwave solutions that transmit broadband voice, video, and data, as well as enable service providers, government agencies, enterprises, and other organizations; harmony enhanced MC; fastback intelligent backhaul radio (IBR); and in-band full-duplex technology. It also provides tethered drones and aerostats for use in intelligence, surveillance, reconnaissance, and tactical communication, as well as communication platform for national defense and security customers; and edge compute capable 4G LTE and 5G network radio. In addition, the company offers repairs, support and maintenance, drones, consulting, and warranties as well as other services. The company was formerly known as Drone Aviation Holding Corp. and changed its name to COMSovereign Holding Corp. in November 2019. COMSovereign Holding Corp. was incorporated in 2014 and is based in Tucson, Arizona.

Cyclo Therapeutics

NASDAQ:CYTHW
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.
GeoVax Labs logo

GeoVax Labs

NASDAQ:GOVXW
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.